Last reviewed · How we verify
NCT05462795
Liquid Biopsy for Early Non-small Lung Cancer Detection
trial testing Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule in Non Small-cell Lung Cancer in 171 participants. Completed in 22 March 2024.
22 March 2024
Quick facts
| Lead sponsor | University of Arizona |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 171 |
| Start date | 2 August 2022 |
| Primary completion | 22 March 2024 |
| Estimated completion | 22 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule
- Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection
- Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer
- Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Conditions studied
- Non Small-cell Lung Cancer — all drugs for Non Small-cell Lung Cancer →
Sponsor
University of Arizona
Who can join
18 and older, any sex, with Non Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774
Verify or expand the search:
- PubMed search for NCT05462795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Arizona trials
Trials by the same sponsor.
- NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
- NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
- NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
- NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
- NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05462795 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arizona
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05462795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing